Product Description
Matriks Biotek SHIKARI® S-AIR ELISA Kit (Qualitative)
Enzyme immunoassay for the qualitative determination of free Infliximab (Remsima®) in serum and plasma.
Remsima®, the world first biosimilar mAb (approved in 2013 by EMA). The Agency's Committee for Medicinal Products for Human Use(CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade. Infliximab (Remsima®) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remsima®. This might lead to severe complications. Matriks Biotek Shikari® Antibody to Infliximab® ELISA Kit can be efficiently used for monitoring anti-Infliximab antibodies.
Qualitative Specifications:
Required Volume (µl) | 20 |
Total Time (min) | 140 |
Sample | Serum, Plasma |
Sample Number | 96 |
Detection Limit (ng/mL) | 30 |
Spike Recovery (%) | Between 85-115 |
Shelf Life (year) | 1 |
Documentation
Download IFU (Qualitative)
Download MSDS (Qualitative)
Please note that the documentation provided is for reference use only. For the most updated version, please contact us.
For Research Use Only
Manufactured by Matriks Biotek Co.
Questions about this product? Ready to place an order? Email us at orders@iwai-chem.com or give us a call: (650) 486-1541 |